- Shannon Turley was inducted into the National Academy of Sciences. A top U.S. honor recognizing her impact in immunology and oncology.
- Turning insight into impact. Her work helps drive new approaches to treating cancer, fibrosis and autoimmune disease.
- A milestone that underscores lasting impact. Her recognition reflects both scientific leadership and progress for patients.
Amgen scientist Shannon Turley, Ph.D., has been inducted into the National Academy of Sciences (NAS), one of the highest honors for researchers in the U.S., recognizing her contributions to advancing biomedical science.
Notably, Turley helped reshape scientific understanding of the immune system through her research uncovering the role stromal cells play in controlling immune responses, especially in cancer, by showing how tumor stroma can create resistance to cancer immunotherapies. This work helped explain how the immune system recognizes and attacks cancer and had a direct influence on strategies for improving cancer immunotherapies.
As Amgen's vice president of Research, and co-head, Research Biology, Turley continues to play an important role in turning complex biology into insights that can support the development of new medicines. She is also part of a broader effort to combine advanced science with new technologies like data analytics and machine learning to accelerate drug discovery and improve outcomes for patients.
“Advancing our understanding of the immune system requires both deep curiosity and a commitment to translating science into meaningful progress for patients,” Turley said. “I'm grateful to the mentors, trainees and colleagues who have shaped my journey. This recognition reinforces the importance of pushing the boundaries of discovery, asking the hard questions, and working together to turn insight into real-world impact.”
Induction into the NAS is considered one of the most prestigious achievements in science, honoring individuals for their outstanding and ongoing contributions to research. Turley's recognition highlights both her impact on the field of immunology and Amgen's continued commitment to innovation in science and medicine.
“This is a well-deserved recognition of Shannon's exceptional scientific leadership and the lasting impact of her work on immunology,” said Howard Chang, Amgen's senior vice president of Global Research & chief scientific officer. “Her ability to turn deep biological insights into meaningful advances for patients reflects Amgen's mission to transform science into innovative medicines that improve lives.”
